On November 4, 2025, The EVERY Company, a biotechnology leader pioneering precision fermentation for highly functional proteins, announced the successful close of its $55 million in Series D financing. The round was led by McWin Capital Partners, through the McWin Food Tech Fund, with participation from Main Sequence, Bloom8, TO.VC, Minerva Foods, Grosvenor Food & Ag, New Agrarian, SOSV, and more. The proceeds from the Series D will be used to expand manufacturing capacity, move to profitability, and further expand its reach across the $270 billion egg market – particularly in the high-volume bakery segment. Wilson Sonsini Goodrich & Rosati advised EVERY on the transaction.

The Wilson Sonsini team that advised EVERY included Andrew Hoffman, Sunny Kumar, Michael Murrietta, Utsav Lall, and Joseph Auer.

For more information, please see EVERY’s press release.